Advanced Oncotherapy

AVO: 56.00 3.00 (▲5.66%)

Delayed:2018-02-16 17:08:03
Bid Price 55.00 High Price 58.00
Ask Price 57.00 Low Price 55.00
Open Price 55.00 Spread 3.57%
Prev Close 56.00 Volume 264,631.00

Advanced Oncotherapy Share Price Chart


Historic - 1 year

Advanced Oncotherapy Share Price Information

Name Advanced Oncotherapy Epic AVO
Sector Health Care Equipment & Services ISIN GB00BD6SX109
Activites Advanced Oncotherapy plc (formerly CareCapital Group plc) is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team ADAM, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies. Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as lower treatment related side effects. Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons. Security Type Equity

Key numbers

Latest Share Price (p) 56.00 Net Gearing (%) 5.92
Market Cap (£m) 42.09 Gross Gearing (%) 9.76
Shares in issue (m) 80.94 Debt Ratio 0.00
P/E Ratio -3.06 Debt-to-Equity Ratio 0.00
Divs per share (p) 0.00 Assets / Equity Ratio 1.11
Dividend Yield (%) 0.00 Price to book value 1.24
Dividend Cover 0.00 SROCE (%) -38.81
Earning per share (p) -17.01 EPS Growth (%) -3235.29
52-week high / low (p) 69.00 / 9.75 DPS Growth (%)

Advanced Oncotherapy Broker Views

Date Broker Rec. Price Old target price New target price Notes
27 Feb Beaufort Securities Hold 56.00 Downgrades
25 Jan Beaufort Securities Speculative Buy 56.00 Retains
24 Jan Beaufort Securities Speculative Buy 56.00 Retains
23 Dec Beaufort Securities Speculative Buy 56.00 Retains
16 Dec Beaufort Securities Speculative Buy 56.00 Retains

Advanced Oncotherapy Director Deals

Date Director Type Volume / Price Trade Value
12 Jan 2018 Dr Enrico Vanni Buy 40000 @ 54.50p £21,800.00

Advanced Oncotherapy Company News

Director Deals - Advanced Oncotherapy PLC (AVO)

Dr Enrico Vanni, Non Executive Director, bought 40,000 shares in the company on the 11th January 2018 at a price of 54.50p. The Director now holds 1,263,946 shares.

Story provided by

Director deals data provided by

Advanced Oncotherapy LIGHT system on track

Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, said it remained on schedule with the development of the first LIGHT system. The company said it continued to make significant advancements in the technology development and manufacture of its first LIGHT system following the successful integration and testing of the first Side Coupled Drift Tube Linac with the Radiofrequency Quadrupole and proton source.

It said lower power testing of the individual accelerating SCDTL units had met expectations and results provided confidence that the units were now capable of accelerating a proton beam to 25MeV through the SCDTL.

It said: 'With much of the technological development now de-risked, the company is on target to have a system capable of treating superficial tumours by the end of Q3 2018.'

The company also said that progress at the Harley Street site remained on-track with the next stage of sub-structural work progressing well.

Having completed the piling, further excavation work was now in progress.

Chief executive Nicolas Serandour said: 'I am very pleased that the technological development of our LIGHT system remains on track and, with protons accelerated through three of the main four accelerating structures, the proton source, RFQ and SCDTL, and the design of the fourth accelerating structure already proven, we are confident that we will have a proton therapy system capable of treating superficial tumours by the end of Q3 next year.

'As we come to the end of the year I am delighted that we enter 2018 in a strong position, not only through the technological developments achieved to date, but also through the security of longer-term financing now completed and with good progress to report at our flagship Harley Street site.'

Story provided by

Advanced Oncotherapy inks distribution deal

Advanced Oncotherapy has signed an exclusive distribution agreement to market and sell its LIGHT system across China, Macau, Taiwan, Hong-Kong and South Korea with Yantai CIPU Medical Technology Co.

Under the agreement, Yantai CIPU will make a payment of £16.5 million to Advanced Oncotherapy. At the same time, the company has secured £20.9m of equity investments to fund the continuing technical development of its first LIGHT system and its installation at the Harley Street Proton Therapy Centre.

Chief executive Nicolas Serandour said: 'I am delighted that we have been able to conclude deals to provide shareholders not only with the security of longer-term financing, but which also introduce a new experienced strategic investor with strong distribution capacity and already established commercial interest in Asia, particularly in one of our key target markets, China.

'It is a little over a year now since I took on the role of Chief Executive Officer and I am pleased to note that as the calendar year draws to a close we have successfully integrated and tested the proton source, RFQ and SCDTL significantly de-risking the development process.

'We are also pleased with the progress of the Harley Street site with the next stage of sub-structural work well underway.

'This deal is consistent with our strategy to focus our resources on the technological development of the first LIGHT system and to establish partnerships with those businesses that have a strong track record of market access and a unique expertise in their own geographies.

'With our long-term financing arrangements now well engaged we can continue to focus on making our unique proton therapy technology available to patients around the world.'

At 9:32am: (LON:AVO) Advanced Oncotherapy PLC share price was +20p at 53p

Story provided by

Advanced Oncotherapy operating losses widen

Advanced Oncotherapy's operating losses rose to £7.3m in the six months to the end of June - up from £5.9m last time.

Revenues were nil - unchanged from a year ago - and pre-tax losses increased to £7.8m from £5.9m.

Chief executive Nicolas Serandour said: 'Technological development of our LIGHT system continues to be on track and, through the successful integration and testing of three of the four key structures of LIGHT's accelerating system, we have significantly de-risked the development process and have overcome the greatest technical challenges that this system faces.

'We are now well positioned to accelerate the proton beam through additional SCDTL modules and, beyond that, to integrate the fourth key component, the CCLs.

'The Harley Street site also progresses well and our principal contractor Deconstruct remains on schedule.

'As our technological progress advances we find ourselves in a much stronger position as we assess financing options and we have been encouraged by positive feedback.

'We have been able to put financing agreements in place and we hope to provide an update to shareholders on longer-term financing options in due course. 'We will update shareholders regularly on our future progress and we remain on track to build a proton therapy system capable of treating superficial tumours by the end of Q3 2018.'

Story provided by

FLASH: Advanced Oncotherapy operating losses widen

Story provided by